Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium As A Superdisintegrant: Mechanisms, Formulation Strategies, And Performance Optimization

NOV 17, 202663 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium, an internally cross-linked sodium carboxymethyl cellulose derivative, represents one of the most effective superdisintegrants in modern pharmaceutical formulation science. Distinguished by its unique fibrous structure and multi-modal disintegration mechanisms—including rapid wicking, volumetric swelling, and elastic deformation recovery—croscarmellose sodium achieves superior tablet disintegration at remarkably low use levels (typically 0.5–6% w/w) compared to alternative superdisintegrants such as crospovidone or sodium starch glycolate. This technical review examines the molecular basis of its superdisintegrant functionality, particle engineering strategies to optimize performance across diverse dosage forms, and formulation considerations critical to R&D professionals developing immediate-release solid oral dosage forms with stringent bioavailability and patient compliance requirements.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Croscarmellose Sodium

Croscarmellose sodium (also known as cross-linked carboxymethyl cellulose sodium, CMC-Na) is synthesized via internal cross-linking of carboxymethyl cellulose chains, yielding a three-dimensional polymeric network that is water-insoluble yet highly hydrophilic 1. The cross-linking reaction typically employs agents such as propylene glycol under acidic conditions (pH 1.0–3.0), resulting in a material that retains the fibrous morphology of the parent cellulose while exhibiting dramatically enhanced swelling capacity and minimal viscosity generation upon hydration 7. This structural architecture differentiates croscarmellose sodium from linear or lightly substituted cellulose derivatives: the cross-linked network prevents dissolution and gel formation, instead promoting rapid water uptake through capillary action (wicking) along the fibrous matrix 10. Commercially available grades such as Ac-Di-Sol® (FMC Corporation), Primellose® (Avebe), Vivasol® (JRS), and DISOLCEL® (Mingtai Chemical) exhibit median particle sizes (D50) ranging from approximately 25 µm to 86 µm, with specific surface areas typically ≥0.3 m²/g 10 12. The degree of cross-linking and particle size distribution are critical quality attributes that govern disintegration kinetics, compressibility, and compatibility with active pharmaceutical ingredients (APIs).

The term "superdisintegrant" denotes excipients capable of achieving rapid tablet disintegration at fractional dosages relative to conventional disintegrants (e.g., starch, unmodified cellulose) 2 5. Croscarmellose sodium, crospovidone (cross-linked polyvinylpyrrolidone), and sodium starch glycolate constitute the three major classes of superdisintegrants 4 10. Among these, croscarmellose sodium is distinguished by its fibrous structure, which imparts unique mechanical and hydrodynamic properties: upon contact with aqueous media, the fibers swell anisotropically and exhibit partial elastic recovery, generating localized stress that disrupts the tablet matrix 3 10. This multi-modal mechanism—wicking, swelling, and deformation recovery—enables croscarmellose sodium to outperform crospovidone and sodium starch glycolate in terms of disintegration speed and consistency, particularly in formulations compressed at high forces or containing hydrophobic APIs 3 4.

Disintegration Mechanisms: Wicking, Swelling, And Deformation Recovery

The superdisintegrant efficacy of croscarmellose sodium arises from three synergistic mechanisms that operate on distinct timescales and length scales within the tablet microstructure 10 12:

  • Wicking (Capillary Action): The fibrous, porous architecture of croscarmellose sodium particles facilitates rapid ingress of water into the tablet core via capillary forces. This initial wetting phase occurs within seconds and is critical for initiating disintegration in low-porosity or hydrophobic formulations 3 10.
  • Volumetric Swelling: Upon hydration, the cross-linked carboxymethyl cellulose chains absorb water and expand, generating internal pressure that mechanically disrupts interparticulate bonds. Unlike sodium starch glycolate, which can form viscous gels at high concentrations (≥5% w/w) and paradoxically retard disintegration 10 12, croscarmellose sodium maintains a non-gelling, fibrous morphology even at elevated hydration levels, ensuring consistent performance across a wide concentration range 3 4.
  • Elastic Deformation Recovery: The fibrous structure of croscarmellose sodium exhibits partial elastic recovery following compression, contributing to stress relaxation within the tablet matrix. This phenomenon is particularly pronounced in formulations compressed at high forces (≥8 kN), where croscarmellose sodium-containing tablets demonstrate earlier onset of disintegration compared to crospovidone-based formulations 3.

Comparative disintegration studies using small-volume texture analysis (simulating limited saliva conditions in the oral cavity) reveal that tablets containing 2% w/w croscarmellose sodium exhibit a gradual, continuous disintegration profile with initial softening at approximately 18 seconds (6 kN compression) and 22 seconds (8 kN compression), whereas 5% w/w crospovidone formulations display a delayed plateau phase followed by abrupt disintegration at 30–40 seconds 3. This kinetic difference translates to superior mouthfeel and patient acceptability for croscarmellose sodium-based orally disintegrating tablets (ODTs), as confirmed by sensory panel evaluations 3.

Particle Size Engineering And Performance Optimization

Recent advances in particle engineering have demonstrated that the median particle size (D50) and particle size distribution of croscarmellose sodium profoundly influence disintegration kinetics, compaction behavior, and formulation robustness 10 11 12. Two distinct particle size regimes have been identified, each offering unique advantages for specific dosage form applications:

Fine Particle Croscarmellose (D50 = 5–36 µm)

Fine particle croscarmellose, characterized by D50 values of 5–36 µm, volume mean diameter (D[4,3]) ≤40 µm, and specific surface area ≥0.3 m²/g, exhibits enhanced wicking efficiency and accelerated disintegration in low-dose, high-compaction formulations 10 12 13. The reduced particle size increases the total surface area available for water uptake, thereby shortening the lag time to disintegration onset. Typical particle size distributions for fine-grade croscarmellose include D10 ≤15 µm and D90 ≤80 µm, ensuring uniform dispersion within the tablet matrix and minimizing the risk of localized over-wetting or incomplete disintegration 10 12. Fine particle croscarmellose is particularly advantageous in formulations containing poorly water-soluble APIs (BCS Class II/IV), where rapid matrix disruption is essential to maximize surface area for dissolution 10 13.

Coarse Particle Croscarmellose (D50 ≥56 µm)

Conversely, coarse particle croscarmellose (D50 ≥56 µm) has been shown to extend the effective concentration range of croscarmellose sodium to ≥4% w/w, a regime where conventional grades (D50 ~34 µm) exhibit diminished disintegration efficiency due to excessive swelling and potential pore blockage 11. Comparative studies demonstrate that tablets containing 4–5% w/w coarse croscarmellose (D50 = 59–86 µm) achieve disintegration times comparable to or faster than formulations with 0.5–2% w/w conventional-grade croscarmellose, even at elevated compaction forces (≥10 kN) 11. This performance enhancement is attributed to the larger interstitial voids created by coarse particles, which facilitate water penetration and prevent gel-layer formation at the particle–matrix interface 11. Coarse croscarmellose is therefore recommended for high-drug-load formulations (API content ≥40% w/w) or sustained-release matrix systems requiring controlled disintegration kinetics 11.

Formulation Strategies And Excipient Compatibility

The integration of croscarmellose sodium into pharmaceutical formulations requires careful consideration of API physicochemical properties, granulation method, and co-excipient selection to achieve optimal disintegration and bioavailability 1 4 5 14.

Granulation Techniques: Intragranular Vs. Extragranular Addition

Croscarmellose sodium may be incorporated either intragranularly (within the granulation phase) or extragranularly (blended with dried granules prior to compression), with each approach offering distinct advantages 4 14:

  • Intragranular Addition: Incorporating croscarmellose sodium into the granulation substrate (typically as a 2–15% w/w slurry relative to API mass) ensures intimate coating of API particles, enhancing wetting and disintegration of hydrophobic or water-unstable actives 1 4 14. For example, formulations of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate (a hydrophobic, thioester-containing CETP inhibitor) employ intragranular croscarmellose sodium (up to 6% w/w) in combination with hygroscopic polymers (HPMC, HPC) to protect the API from hydrolysis while maintaining rapid disintegration 1 5 6 8. The granulation process involves mixing the API with crospovidone (micronized), microcrystalline cellulose (MCC), croscarmellose sodium, and HPMC, followed by spraying with an aqueous or hydroalcoholic HPMC solution (≤0.5% w/w), drying, and final blending with extragranular MCC, colloidal silicon dioxide, and sodium stearyl fumarate 1 5 6 8.
  • Extragranular Addition: Blending croscarmellose sodium with dried granules (typically 1–4% w/w of total tablet weight) is preferred for water-soluble APIs or formulations requiring minimal processing 4 14. This approach minimizes exposure of croscarmellose sodium to moisture during granulation, preserving its swelling capacity and preventing premature activation 4 14.

Co-Excipient Synergies: Microcrystalline Cellulose And Coprocessed Additives

The combination of croscarmellose sodium with microcrystalline cellulose (MCC) and coprocessed MCC–alginate complexes (e.g., Avicel® AC-815, comprising 75–95% MCC and 5–25% calcium/sodium alginate) has been shown to enhance both compressibility and suspendibility of rapidly disintegrating tablets 4 14. In formulations designed for pediatric or geriatric populations, where dose administration as an aqueous suspension is preferred, the inclusion of 10–50% w/w MCC and 10–50% w/w coprocessed MCC–alginate complex (in addition to 1–6% w/w croscarmellose sodium) yields tablets that disintegrate within 30 seconds and form homogeneous, non-settling suspensions suitable for oral administration 4 14. The MCC component provides plastic deformation during compression, ensuring adequate tablet hardness (tensile strength ≥0.5 MPa), while the alginate complex imparts suspending properties by forming a weakly structured network upon hydration 4 14.

Lubricant Selection And Disintegration Kinetics

The choice of lubricant significantly impacts the disintegration performance of croscarmellose sodium-containing tablets, as hydrophobic lubricants (e.g., magnesium stearate) can coat particle surfaces and impede water penetration 1 4. Sodium stearyl fumarate, a hydrophilic lubricant, is recommended for formulations requiring rapid disintegration (≤30 seconds), as it minimizes interference with wicking and swelling mechanisms 1 5 6 8. Lubricant concentrations should be limited to 0.1–2.0% w/w to avoid excessive hydrophobicity 3.

Applications In Orally Disintegrating Tablets (ODTs) And Immediate-Release Formulations

Croscarmellose sodium is the superdisintegrant of choice for orally disintegrating tablets (ODTs), a dosage form designed to disintegrate rapidly (typically ≤30 seconds) in the oral cavity without water, thereby improving patient compliance, particularly in pediatric, geriatric, and dysphagia populations 3. The optimal concentration of croscarmellose sodium in ODT formulations is 0.5–2.0% w/w (relative to total tablet weight), significantly lower than the 5% w/w typically required for crospovidone or sodium starch glycolate 3. This low-dose efficacy translates to cost savings, reduced tablet weight, and improved mechanical strength, as excessive superdisintegrant levels can compromise tablet hardness and friability 3.

Case Study: Stability And Performance Of Low-Superdisintegrant ODTs

A comprehensive stability study of direct-compression ODTs containing 0.3–2.0% w/w croscarmellose sodium, a polyol matrix (spray-dried mannitol), microcrystalline cellulose (≤10% w/w), and a model API demonstrated that formulations with 0.5–2.0% w/w croscarmellose sodium maintained disintegration times ≤30 seconds (excess water test) and tensile strength ≥0.5 MPa after four months of storage under accelerated conditions (40°C/75% RH) 3. In contrast, formulations with ≥5% w/w crospovidone exhibited increased disintegration times (≥40 seconds) and reduced mechanical integrity due to hygroscopicity-induced softening 3. Sensory panel evaluations confirmed that croscarmellose sodium-based ODTs provided a smoother mouthfeel and faster perceived disintegration compared to crospovidone-based counterparts, attributed to the gradual, continuous disintegration profile of croscarmellose sodium 3.

Pharmaceutical Suspension Tablets For Pediatric And Geriatric Use

Croscarmellose sodium is also employed in suspension tablet formulations, which disintegrate rapidly in a small volume of water (e.g., 5–10 mL) to form a homogeneous suspension suitable for dose administration via oral syringe or spoon 4 14. These formulations typically contain 1–6% w/w croscarmellose sodium, 10–50% w/w MCC, and 10–50% w/w coprocessed MCC–alginate complex, and are prepared via wet granulation using a croscarmellose sodium slurry (2–15% w/w relative to API mass) as the granulating fluid 4 14. The resulting tablets disintegrate within 30 seconds and form suspensions that remain homogeneous for ≥5 minutes, ensuring accurate dosing and palatability 4 14. This dosage form is particularly advantageous for water-insoluble APIs (e.g., ibuprofen, azithromycin), where rapid matrix disruption maximizes surface area for dissolution and absorption 4 14.

Comparative Performance: Croscarmellose Sodium Vs. Alternative Superdisintegrants

Systematic comparisons of croscarmellose sodium, crospovidone, and sodium starch glycolate reveal distinct performance profiles that inform superdisintegrant selection for specific formulation challenges 3 4 10 12:

  • Disintegration Efficiency: Croscarmellose sodium achieves equivalent or superior disintegration at 2% w/w compared to 5% w/w crospovidone or sodium starch glycolate, due to its multi-modal mechanism (wicking + swelling + deformation recovery) 3 10.
  • Compaction Tolerance: Croscarmellose sodium maintains disintegration performance at high compaction forces (≥8 kN), whereas crospovidone exhibits delayed disintegration onset under equivalent conditions 3.
  • Concentration-Dependent Behavior: Sodium starch glycolate forms viscous gels at concentrations ≥5% w/w, paradoxically increasing disintegration time, whereas croscarmellose sodium (particularly coarse grades) extends effective concentration range to ≥4% w/w without gelling 10 11 12.
  • Hydrophobic API Compatibility: Croscarmellose sodium's fibrous structure and wicking capacity make it superior for formulations containing hydrophobic or poorly wettable APIs, where rapid water ingress is critical [
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATIONOrally disintegrating tablets (ODTs) for pediatric and geriatric populations, immediate-release solid oral dosage forms requiring rapid disintegration (≤30 seconds) with limited water availability.Ac-Di-SolAchieves rapid tablet disintegration at 0.5-2% concentration (vs 5% for crospovidone), maintains disintegration under high compaction forces (≥8 kN), provides superior mouthfeel with gradual disintegration profile in orally disintegrating tablets.
FMC CORPORATIONHigh-compaction formulations containing BCS Class II/IV APIs, low-dose tablets requiring rapid matrix disruption to maximize dissolution surface area.Fine Particle Croscarmellose (D50=5-36 μm)Enhanced wicking efficiency and accelerated disintegration in low-dose formulations due to increased surface area (≥0.3 m²/g), shortened lag time to disintegration onset, optimal for poorly water-soluble APIs.
FMC CORPORATIONHigh-drug-load formulations (API content ≥40%), sustained-release matrix systems requiring controlled disintegration kinetics, tablets compressed at high forces.Coarse Particle Croscarmellose (D50≥56 μm)Extends effective concentration range to ≥4% without gel formation, achieves comparable disintegration to conventional grades at 0.5-2% even at elevated compaction forces (≥10 kN), prevents pore blockage through larger interstitial voids.
FMC CORPORATIONPediatric and geriatric dose administration via oral syringe or spoon, water-insoluble APIs (e.g., ibuprofen, azithromycin) requiring maximized surface area for dissolution and absorption.Pharmaceutical Suspension TabletsRapid disintegration within 30 seconds in small water volumes (5-10 mL), forms homogeneous suspensions stable for ≥5 minutes using 1-6% croscarmellose sodium with MCC and alginate complex, ensures accurate dosing.
F. HOFFMANN-LA ROCHE AGImmediate-release tablets containing hydrophobic and water-unstable active pharmaceutical ingredients, formulations requiring protection from hydrolysis with maintained rapid disintegration performance.CETP Inhibitor FormulationIntragranular croscarmellose sodium (up to 6%) combined with hygroscopic polymers (HPMC, HPC) protects hydrophobic thioester-containing API from hydrolysis while maintaining rapid disintegration, ensures chemical stability in moisture-sensitive formulations.
Reference
  • A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium
    PatentActiveIL225780A0
    View detail
  • A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
    PatentActiveMY164729A
    View detail
  • Stable Orally Disintegrating Tablets Having Low Superdisintegrant
    PatentInactiveUS20110105441A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png